Leerink Partners Reiterates Buy Rating on RAPP
Leerink Partners maintains its buy rating on RAPP, setting a target price of $52, a 30% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on RAPP on June 24, 2026, with a price target of $52.
- Leerink Partners's $52 price target implies 30% upside from Rapport Therapeutics, Inc.'s ($RAPP) current $40 share price.
- RAPP shares traded near $38.88 on Wednesday, with recent insider buying activity noted.
- Peers like FMR LLC and TRV GP V, LLC hold significant shares in RAPP, with varied recent activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Leerink Partners reaffirmed its buy rating on RAPP, setting a price target of $52. Analyst Marc Goodman led the review, indicating confidence in the stock's potential. RAPP shares were trading close to $38.88 on Wednesday.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in RAPP
FMR LLC increased its holdings in RAPP by 57,074 shares, bringing its total to about 7.17 million shares valued at approximately $224.3 million. TRV GP V, LLC maintained its position with around 7.14 million shares worth $223.3 million. ARCH VENTURE MANAGEMENT, LLC also held steady with about 3.73 million shares valued at $116.7 million. Meanwhile, CAPITAL INTERNATIONAL INVESTORS reduced its stake by 304,556 shares, now holding about 3.10 million shares valued at $96.9 million. CORMORANT ASSET MANAGEMENT, LP cut its holdings by 70,000 shares, ending with approximately 2.96 million shares worth $92.5 million.
Insider Buying and Selling at Rapport Therapeutics, Inc.
On June 10, 2026, several insiders, including John Maraganore, Paul Silva, Wendy Young, Ramiro Sanchez, James Healy, and Reid Huber, each bought 15,200 shares of RAPP. These transactions were not part of any pre-arranged trading plan.
Analysts Set New Price Targets
On June 24, 2026, Leerink Partners reiterated its buy rating for RAPP with a $52 price target. Previously, on May 21, 2026, BTIG maintained a buy rating with a $65 target, and on May 19, 2026, Truist Securities assumed a buy rating with a $56 target. The consensus rating for RAPP remains a buy, with an average target price reflecting optimism among analysts.
Bottom Line
Leerink Partners' reiteration of a buy rating for RAPP suggests continued confidence in the company's prospects. The stock, trading near $38.88, is supported by insider buying and significant institutional holdings. While analyst targets vary, the overall sentiment remains positive, reflecting expectations of growth.
Get Rapport Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RAPP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.